Skip to main content

Chordoma

5
Pipeline Programs
8
Companies
8
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
3
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
267%
Monoclonal Antibody
133%
+ 7 programs with unclassified modality

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Nordic Pharma
Nordic PharmaFrance - Paris
2 programs
1
1
BN-Brachyury plus radiationPhase 2
TAEK-VAC-HerByPhase 1
Biocorp
BiocorpFrance - Issoire
1 program
1
BL-B01D1Phase 21 trial
Active Trials
NCT06787664Active Not Recruiting27Est. Dec 2027
Sandoz
SandozAustria - Kundl
1 program
1
imatinibPhase 2Small Molecule1 trial
Active Trials
NCT00150072Completed55Est. Apr 2008
Prevail Therapeutics
1 program
1
PemetrexedPhase 11 trial
Active Trials
NCT03955042Completed15Est. Jan 2023
Bavarian Nordic
Bavarian NordicDenmark - Kvistgard
2 programs
TAEK-VAC-HerByPHASE_11 trial
BN-Brachyury plus radiationPHASE_21 trial
Active Trials
NCT04246671Completed37Est. Dec 2024
NCT03595228Completed29Est. Jan 2022
ImmunityBio
ImmunityBioSAN DIEGO, CA
1 program
Aldoxorubicin HydrochloridePHASE_1_21 trial
Active Trials
NCT03647423Withdrawn0Est. Dec 2021
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
AfatinibPHASE_2Small Molecule1 trial
Active Trials
NCT03083678Completed43Est. Jan 2025
Bristol Myers Squibb
1 program
NivolumabPHASE_2Monoclonal Antibody1 trial
Active Trials
NCT03623854Completed10Est. Sep 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
BiocorpBL-B01D1
Bristol Myers SquibbNivolumab
Bavarian NordicBN-Brachyury plus radiation
Boehringer IngelheimAfatinib
Sandozimatinib
ImmunityBioAldoxorubicin Hydrochloride
Bavarian NordicTAEK-VAC-HerBy
Prevail TherapeuticsPemetrexed

Clinical Trials (8)

Total enrollment: 216 patients across 8 trials

NCT06787664BiocorpBL-B01D1

A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma

Start: Jan 2025Est. completion: Dec 202727 patients
Phase 2Active Not Recruiting
NCT03623854Bristol Myers SquibbNivolumab

Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma

Start: Apr 2019Est. completion: Sep 202310 patients
Phase 2Completed
NCT03595228Bavarian NordicBN-Brachyury plus radiation

BN Brachyury and Radiation in Chordoma

Start: Oct 2018Est. completion: Jan 202229 patients
Phase 2Completed
NCT03083678Boehringer IngelheimAfatinib

Afatinib in Locally Advanced and Metastatic Chordoma

Start: Jun 2018Est. completion: Jan 202543 patients
Phase 2Completed
NCT00150072Sandozimatinib

Efficacy and Safety of Imatinib in Chordoma

Start: Oct 2004Est. completion: Apr 200855 patients
Phase 2Completed
NCT03647423ImmunityBioAldoxorubicin Hydrochloride

QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.

Start: Aug 2018Est. completion: Dec 20210
Phase 1/2Withdrawn
NCT04246671Bavarian NordicTAEK-VAC-HerBy

TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer

Start: Aug 2020Est. completion: Dec 202437 patients
Phase 1Completed
NCT03955042Prevail TherapeuticsPemetrexed

Pemetrexed for the Treatment of Chordoma

Start: Sep 2019Est. completion: Jan 202315 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.